January 2021 Awareness Night Treatment of Advanced Prostate Cancer: From A(palutamide) to Z(ytiga(tm)) Dr. Urban Emmenegger, MD Medical Oncologist, Odette Cancer Centre (Div. of Medical Oncology) and Sunnybrook Research Institute (Biological Sciences Platform) Assistant Professor, Dept. of Medicine, U. of Toronto Associate Member, Inst. of Medical Science, U. of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 2:15:05 <
According to a news release just issued by Queen’s University, Belfast, a group of 150 researchers around the world is coming together to expand enrollment and access to the Australian INTERVAL trial into a global trial to test whether serious exercise should be prescribed as part of the treatment for men with advanced prostate cancer. Read the article.
Chemotherapy at the start of hormone therapy can extend the lives of men with prostate cancer that has spread beyond the gland, a new study finds. Over nearly 29 months of follow-up, men with advanced prostate cancer who received the combination therapy lived almost 14 months longer than men who received only hormone therapy (58 months versus 44 months), researchers said. Read the article.
Androgen deprivation therapy (ADT) may increase diabetes risk. As benefits of primary ADT (PADT) for localized PCa are controversial, and most PCa survivors are of advanced age with comorbidities, it is important to determine if PADT increases diabetes risk and what are the susceptibility factors. Read the article. (Free UroToday login required.)
UroToday has expanded its video-on-demand content in the UrologyTUBE™ with a new video channel featuring multi-media lectures focusing on treatment of men with advanced prostate cancer. The new channel specifically focuses on androgen deprivation treatment (hormone treatment) as the backbone of advanced prostate cancer treatment. View the channel. (Free UroToday login required.)
Research hope for prostate cancer Pouring petrol on the fire can potentially reverse resistance to hormone treatments for prostate cancer, new research suggests. The counter-intuitive strategy called bipolar androgen therapy (BAT) involves boosting levels of the male hormone testosterone, which normally stimulates prostate cancer growth. In a small pilot study, scientists found that alternating high and low testosterone levels caused seven of 16 patients with resistant prostate cancer to go into remission. Read the article.
The year 2014 has again provided important developments in the area of prostate cancer. New data and new treatments span the spectrum of prostate cancer management, from prevention and screening to optimal strategies for localized, locally advanced, and metastatic disease. Read the article. (Free Medscape account required.)